Iambic Therapeutics, Inc. IAM
Set alert
At close · Oct 30
After hours · Oct 30, 7:11 PM ET
- YTD
- -28.98%
- 1 year
- -28.98%
- Open
- 13.10
- Prev close
- 14.28
- Mkt cap
- 636.59M
- Vol
- 476.86K
- Avg vol
- 1.06M
- EPS
- -2.69
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 12.40
- High
- 13.55
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 18.91
- 200-d avg
- 18.91
- 1y target
- 0.00
News
-
5 days ago benzinga.com
Iambic Therapeutics Presents Updated Clinical Results From Its IAM1363 Inhibitor At ESMO Congress 2026
Iambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life sciences and technology company developing novel medicines using its AI-driven platform, today announced updated clinical data…
5 days ago businesswire.com
Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers
SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life sciences and technology company developing novel medicines using its AI-driven platform, today…
2 weeks ago seekingalpha.com
U.S. IPO Weekly Recap: Biotechs City Therapeutics And Iambic Headline The Week's Pricings
Three IPOs and two SPACs priced this week, and two SPACs submitted filings. No IPOs are currently scheduled for the week ahead as the year's next mega IPO potentially comes into view. Street research…
2 weeks ago businesswire.com
Iambic Announces Pricing of Initial Public Offering
SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform, today…
3 weeks ago reuters.com
Nvidia-backed Iambic Therapeutics targets up to $806 million valuation in US IPO
Iambic Therapeutics, which is backed by Nvidia , is aiming to raise as much as $159.4 million in its US IPO, a regulatory filing showed on Thursday, as biotech companies remain a bright spot in an…
4 months ago zacks.com
Docusign Declines 7.2% Since Beating Q1 Earnings & Revenue Estimates
DOCU tops Q1 fiscal 2027 earnings and revenue estimates as IAM adoption accelerates, profitability improves and ARR growth confidence strengthens.
2 years ago businesswire.com
New Bitdefender Survey of 1,200 Cybersecurity Professionals Reveals Top Concerns and Challenges for Businesses Globally
BUCHAREST, Romania & SANTA CLARA, Calif.--(BUSINESS WIRE)--Bitdefender report reveals that increased data breaches and overall pressure Is driving 64% to look for new jobs in the next 12 months.
2 years ago businesswire.com
Entrust Completes Acquisition of Onfido, Creating A New Era of Identity-Centric Security
MINNEAPOLIS--(BUSINESS WIRE)--Entrust, a global leader in trusted payments, identities, and data security, today announced that it has completed its acquisition of Onfido, a global leader in identity…
-
7 years ago benzinga.com
65 Stocks Moving In Thursday's Mid-Day Session
65 Stocks Moving In Thursday's Mid-Day Session
-
8 years ago benzinga.com
Stocks Which Set New 52-Week Low Yesterday, October 3rd
Stocks Which Set New 52-Week Low Yesterday, October 3rd
-
8 years ago benzinga.com
32 Stocks Moving In Thursday's Mid-Day Session
32 Stocks Moving In Thursday's Mid-Day Session
-
8 years ago benzinga.com
Mid-Morning Market Update: Markets Open Lower; Constellation Brands Beats Q2 Expectations
Mid-Morning Market Update: Markets Open Lower; Constellation Brands Beats Q2 Expectations
-
8 years ago benzinga.com
43 Stocks Moving In Wednesday's Mid-Day Session
43 Stocks Moving In Wednesday's Mid-Day Session
-
8 years ago benzinga.com
I-AM Capital Acquisition Company Confirms Payment Of Funds To Extend Period To Complete A Business Combination
I-AM Capital Acquisition Company Confirms Payment Of Funds To Extend Period To Complete A Business Combination